FOR PATIENTS
FOR CLINICIANS
FOR THE PRESS
THE EXPERTS GROUP
MEDIA POOL
> SIRT > Home > EXPLOSIVE study
 

EXPLOSIVE

 

Study title

 

Predictive Value of 99mTc- Albumin Spheres Before 90Y-SIR Therapy (EXPLOSIVE)

http://clinicaltrials.gov/ct2/show/NCT01186263

Around a week before carrying out Selective Internal Radiation Therapy (SIRT), doctors simulate the treatment using angiography. They inject a test dose of weakly radioactive microspheres into the hepatic artery in order to be able to assess the subsequent distribution of the yttrium-90 microspheres inside the body. The EXPLOSIVE study uses a Technetium-99-labelled albumin microparticle (Tc-99m-MAA) for this and also Technetium-99-labelled HSA microspheres B20 (Tc-99m-HSA). The results will provide information regarding which particles allow the best assessment of the distribution of the actual SIR-Spheres® microspheres.

  • Metastases that are inoperable and which occur primarily or exclusively in the liver
  • Life expectancy of at least 3 months without active treatment
  • Adequate haematological, renal and liver function
  • No ascites, no cirrhoses, portal vein hypertension
  • No previous radiation to the upper abdomen
  • No previous chemotherapy
  • No pregnancy or breastfeeding
  • No further malignant underlying disease
  • WHO performance status 0-1

 

Further criteria can be viewed be clicking this link: http://clinicaltrials.gov/ct2/show/NCT01186263

 

The hospital below will also be happy to answer any queries.

MAGDEBURG

University Hospital of Magdeburg
Department of Radiology and Nuclear Medicine
Building 40
Leipziger Straße 44
D-39120 Magdeburg

Study secretary
Christel Besseler
Tel.: +49 (0)391 671-3071
E-mail: christel.besseler@med.ovgu.de

www.med.uni-magdeburg.de

www.zegit.ovgu.de

 
NEWS & DATES
More treatment options are necessary for patients with metastatic colorectal cancer – Colorectal cancer prevention is getting more and more attention. However, every third colorectal cancer patient develops metastases in the course of the disease – often in the liver. For these patients, more and better therapy options are needed. Local therapies offer promising opportunities.To the press release
The new ESMO guidelines recommend SIRT for people with metastatic colorectal cancer if the metastases are limited to the liver and are not responding to chemotherapy.
New evidence of the benefits of SIRT in mCRC – The depth-of-response data from the SIRFLOX study shows a significantly larger local depth of response through the combination of SIRT and chemotherapy. To the press release
Metastatic colorectal cancer: the SIRFLOX, FOXFIRE and FOXFIRE Global studies are investigating the benefits of combining SIRT with chemotherapy. The data from the three studies regarding overall survival is expected by the end of 2017. The SARAH and SIRveNIB studies on advanced liver cell cancer are now complete. Both compared Y90 radio-embolisation with sorafenib chemotherapy. The initial results are set to be published at the end of 2016 (SARAH) and 2017 (SIRveNIB).
The SIRT Experts Group is a partner of: